Effective immunomodulating treatment of virus-associated states in gynecology (HPV, HSV, CMV)
Victoriia Bobrytska (UA)
[Bobrytska] Kharkiv Medical Academy of Postgraduate Education
Context Genital mixt-infection in cooperation with virus infection is a reason of neoplastic processes both in women or men organism. Including of the immunomodulating and oprotecting medicines in the treatment of infectious lesions is logical due to immunosuppressed state. Objective is to increase the effectiveness of the treatment of virus-associated pathological states with the use of interferon alpha-2b and onco-protector epygallocathehine-3-gallat (EGCG) with indol-3-carbinol (I3C) Methods & patients Under a supervision there were 110 women in age from 24 to 35 years with genital mixt-infection, including HPV, HSV II, CMV. Basic group 80 person, control – 30.The courses of antibiotic, antifungial, antiherpetic medicine (valacyclovir) were conducted. The courses of immunomodulating therapy were conducted – an injection of interferon alpha-2b course - 30 million, and then EGCG 90mg with I3C 400mg during 3-6 monthes. Immunomodulating therapy had also a purpose to diminish viral loading of HPV in an organism, EGCG with I3C – onco-protecting effects. Results Basic group: the negative PCR HPV in 57,6%, HSV II - 34,3%, chlamydia infection -79% patients, ureaplasma 86,2%, the bacterial 94,7% patients. After the repeated courses of interferonotherapy plus course of inductors of interferon negative results of HPV infection were received for 86,7%, HSV II - 68,5%, chlamydia - 92.1%, ureaplasma - 98,1%. Control group: no elimination of HPV, lowering HSV, relapse of CIN I 14% , CIN II 2%, relapse of condyllomas 24%. Conclusions Immunomodulating therapy promotes efficiency of the therapy of gynecological infections considerably, including HPV, HHV, CMV. Therapy with EGCG 90 mg and I3C 400mg potentiates onco-protecting effect and can be included with interferon-therapy in the complex of treatments of virus-associated pathologies.